Abstract
Familial hypercholesterolemia (FH) is an inherited metabolic disorder characterized by high levels of plasma low density lipoproteins (LDL) and an increased risk of premature atherosclerosis and coronary heart disease. LDL receptor (LDLr) deficiency is the most prevalent cause of FH. Therefore, hepatocyte-directed LDLr gene transfer constitutes an important strategy for the treatment of this monogenetic disease. Nowadays, homozygous FH patients are treated with lipid-lowering drugs complemented by plasma or LDL apheresis. Liver transplantation can restore metabolism of apolipoprotein B containing lipoproteins, but requires lifelong immunosuppression to prevent organ rejection. Recently, significant progress in gene transfer technology has encouraged investigators to further develop LDLr gene transfer approaches for the treatment of FH. In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression. The first part of this review provides a thorough overview of familial hypercholesterolemia including its diagnosis, lipoprotein metabolism, and current management. In the second part, we critically review experimental LDLr gene transfer studies demonstrating the progress that has been made from the initial proof of principle studies to recent investigations showing dramatic regression of atherosclerosis in experimental models.
Keywords: Familial hypercholesterolemia, gene therapy, low density lipoprotein receptor gene transfer, atherosclerosis, dyslipidemia, cardiac ischemia, acetylcoenzyme A synthetase, C-reactive protein, organ rejection, hepatocytes
Current Pharmaceutical Design
Title: Gene Therapy for Familial Hypercholesterolemia
Volume: 17 Issue: 24
Author(s): Eline Van Craeyveld, Frank Jacobs, Stephanie C. Gordts and Bart De Geest
Affiliation:
Keywords: Familial hypercholesterolemia, gene therapy, low density lipoprotein receptor gene transfer, atherosclerosis, dyslipidemia, cardiac ischemia, acetylcoenzyme A synthetase, C-reactive protein, organ rejection, hepatocytes
Abstract: Familial hypercholesterolemia (FH) is an inherited metabolic disorder characterized by high levels of plasma low density lipoproteins (LDL) and an increased risk of premature atherosclerosis and coronary heart disease. LDL receptor (LDLr) deficiency is the most prevalent cause of FH. Therefore, hepatocyte-directed LDLr gene transfer constitutes an important strategy for the treatment of this monogenetic disease. Nowadays, homozygous FH patients are treated with lipid-lowering drugs complemented by plasma or LDL apheresis. Liver transplantation can restore metabolism of apolipoprotein B containing lipoproteins, but requires lifelong immunosuppression to prevent organ rejection. Recently, significant progress in gene transfer technology has encouraged investigators to further develop LDLr gene transfer approaches for the treatment of FH. In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression. The first part of this review provides a thorough overview of familial hypercholesterolemia including its diagnosis, lipoprotein metabolism, and current management. In the second part, we critically review experimental LDLr gene transfer studies demonstrating the progress that has been made from the initial proof of principle studies to recent investigations showing dramatic regression of atherosclerosis in experimental models.
Export Options
About this article
Cite this article as:
Van Craeyveld Eline, Jacobs Frank, C. Gordts Stephanie and De Geest Bart, Gene Therapy for Familial Hypercholesterolemia, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247550
DOI https://dx.doi.org/10.2174/138161211797247550 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Evaluation of Ischemic Heart Disease Factors in Hemophilia Patients in Khorramabad
Cardiovascular & Hematological Disorders-Drug Targets Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins
Current Medicinal Chemistry Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nanomedicine Against Malaria
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Editorial [Hot Topic: Efficient Strategies for Signalling Pathway Mining (Guest Editors: Qingfeng Chen & Baoshan Chen)]
Current Protein & Peptide Science Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Active Phytochemicals from Chinese Herbs as Therapeutic Agents for the Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery The Coronary Circulation in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Atorvastatin-Loaded Oleic Acid Nanoglobules for Oral Administration: In Vitro Characterization and Biopharmaceutical Evaluation
Current Nanoscience Approaches to the Management of Acute Kidney Injury in Children
Recent Patents on Biomarkers Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology